The autosomal recessive hypercholesterolemia (ARH) gene is located on chromosome 1p35 and encodes a 308-amino acid protein containing a phosphotyrosine-binding domain. Several researchers have identified mutations of ARH that cause autosomal recessive hypercholesterolemia; however, it remains unknown whether this gene is involved in common hypercholesterolemia.
Introduction
Low-density lipoprotein (LDL) particles are the major cholesterol transport vehicle in the circulation and approximately 70% of the cholesterol in human plasma is found in the LDL fraction. Most circulating mutation of the LDLR gene, was identified 7) . This disorder is called autosomal recessive hypercholesterolemia (ARH) and the ARH gene is located on chromosome 1p35-36.1, and encodes a 308 amino acid protein containing a phosphotyrosine-binding (PTB) domain 7) . This PTB domain binds to the consensus amino acid sequence NPVY, which is present in the cytoplasmic domain of LDLR. A normal NPVY sequence in the cytoplasmic tail of LDLR is absolutely essential for internalization of this receptor 8, 9) . In addition to binding with LDLR, ARH also binds to the 2-adaptin subunit of AP-2 and the terminal domain of clathrin via a specific sequence (LLDLE) in vitro, so it has been proposed that ARH may link LDLR to the endocytotic machinery 7, 10) . Several researchers, including us, have identified various mutations of the ARH gene that cause autosomal recessive hypercholesterolemia 7, [11] [12] [13] [14] [15] [16] [17] , but it remains unknown whether this gene is relevant to common hypercholesterolemia. In the present study, we searched for single nucleotide polymorphisms (SNPs) of the ARH gene, including the 5'-flanking region, determined the haplotype structure for each polymorphism, and evaluated the association between ARH polymorphisms/haplotypes and hypercholesterolemia.
Methods

Subjects
The 1,800 Japanese individuals randomly selected from the Suita municipal population registry were enrolled in the present study. Written informed consent was obtained from all of the participants and the study design was approved by the institutional research board and ethics committee of the National Cardiovascular Center and by the Committee on Genetic Analysis and Gene Therapy of the National Cardiovascular Center. According to Adult Treatment Panel criteria, hypercholesterolemia was defined as either plasma total cholesterol (TC) levels ≥ 240 mg/dL, LDL-C levels ≥ 160 mg/dL, or lipid-lowering therapy, while subjects with TC levels 200 mg/dL, LDL-C levels 130 mg/dL, triglyceride (TG) levels 150 mg/dL, and no history of hypercholesterolemia or hypertriglycemia were assigned to the normal control group 18) . As a result, we used 391 subjects with hypercholesterolemia and 495 control subjects for case-control analysis.
We also used another sample of 384 unrelated Japanese with diabetes mellitus screen for a Thr56Met mutation. We also used DNA of 48 unrelated subjects from the patients with diabetes or dyslipidemia for an initial screening of polymorphisms.
SNPs Screening by Denaturing High-Performance Liquid Chromatography
We screened polymorphisms of ARH using denaturing high-performance liquid chromatography because it showed a power 99.3% to detect SNPs with an allele frequency of 0.1 19) . Probes were prepared for the 5'-flanking region, exons 1 − 9, and the 3'-flanking region of ARH. Then the polymerase chain reaction (PCR) was carried out in a reaction mixture (25 L) containing 10 ng genomic DNA, 12.5 pmol of the forward and reverse primers, 0.20 mM of each dNTP, and 0.5 U Taq DNA polymerase (AmpliTaq Gold, Applied Biosystems) with the corresponding buffer. PCR involved initial denaturation at 95 for 10 min, followed by cycles of denaturation at 95 for 15 sec, annealing at the appropriate temperature for 1 min, and extension at 72 for 1 min. Final extension was performed at 72 for 7 min.
The PCR products were heated at 95 for 10 min, followed by incubation at 55 for 10 min to allow heteroduplex formation. DHPLC analysis was performed on a Wave System (Transgenomics). Homozygous and heterozygous genotypes of the PCR products were distinguished according to differences in their melting behavior 20) . The temperatures and acetonitrile gradients were established according to sequence-specific melting profiles based on the predictions of the Stanford Genome Technology Center and Wave-Maker software.
Direct Sequencing
To determine the nucleotide sequence of polymorphisms of ARH, PCR products that showed heteroduplex formation were directly sequenced by an automated protocol, followed by the fluorescent detection of dideoxy termination products with a model ABI 3700 gene analyzer (PE Applied Biosystems).
Genotyping
The detected polymorphisms were genotyped using 5 ng genomic DNA by the TaqMan system according to the manufacturer's protocol (PE Applied Biosystems). The TaqMan-PCR primers and probes are shown in Table 1 .
Comparison of Clinical Measurements Between the Hypercholesterolemia and Control Groups
We compared the clinical measurements between subjects with hypercholesterolemia and control subjects. Clinical measurements were as follows: age, body mass index (BMI), systolic blood pressure (SBP), diastolic blood pressure (DBP), TC, LDL-C, TG, HDL-C, fasting plasma glucose (FPG), hemoglobin A1c (HbA1c). Differences in quantitative variables were tested using ANOVA with adjustment for age and gender. Gender ratios were tested by the 2 test with 1 degree of freedom. All clinical measurements are expressed as the mean SE, and p 0.05 was considered significant.
Association Analysis of the ARH Gene
For each biallelic marker, allele frequencies were calculated from the genotypes of subjects with hypercholesterolemia and the controls. Deviation from the Hardy-Weinberg equilibrium was assessed using the 2 test with 2 degrees of freedom. Haplotype frequencies were estimated by an expectation-maximization algorithm using the LD Support program 21) . Associations between ARH genotypes and hypercholesterolemia were assessed by Fisher's exact test, while those between ARH haplotypes and hypercholesterolemia were assessed by the Z-test. We also performed multiple logistic regression analysis to adjust for age and gender.
Construction of Plasmids
A human liver cDNA library was obtained from Clontech and used as the template for the full-length ARH protein and for the cytoplasmic tail of LDLR. The primer sequences used for cloning ARH and LDLR were as follows: ARH: 5'-CGCGGATCCAT-GGACGCGCTCAAGTCG-3' (forward) and 5'-CGG-AATTCTCAGAAGCTGAAGAGGTC-3' (reverse); LDLR: 5'-CGCGGATCCAAGAACTGGCGGCTT-AAGAACATC-3' (forward) and 5'-CGGAATTCTC-ACGCCACGTCATCCTCCAGACTG-3' (reverse). Restriction sites used for cloning are shown in bold, and template sequences are underlined. PCR was carried out using TaKaRa LA Taq (Takara) in a 50-L 
reaction mixture with 10 pmol of each primer and 25 pmol of each dNTP. PCR products for ARH were digested with BamHI and EcoRI, purified by gel electrophoresis, and ligated into the pET-28a-c ( ) vector (Novagen) immediately downstream and in frame with a sequence encoding six histidine residues. Ligation was used to transform E. coli BL21 (DE3) (Novagen). A plasmid containing the cytoplasmic tail of the LDLR fused to GST was created by ligation of the appropriate PCR product into the BamH1 and HindIII sites of the pGEX-6P-1 vector (Amersham Bioscience). The ligated plasmid was then used to transform E. coli BL21 (Stratagen).
A plasmid encoding the full-length ARH protein with a mutation of the PTB domain (Thr56Met) was generated by site-directed mutagenesis using the GeneTailor TM Site-Directed Mutagenesis System (Invitrogen). The top strands of the oligonucleotides employed were as follows: 5'-CCTCAAGTACCTGG-GCATGATGCTAGTGGAG-3' (forward) and 5'-TCA-TGCCCAGGTACTTGAGGCTGAACAGCATC-3' (reverse). The mutation is indicated in bold and underlined. The construct was confirmed by sequencing.
Pull-Down Assay and Immunoblotting
A pull-down assay was performed using a ProFound TM Pull-Down PolyHis Protein: Protein Interaction kit (Pierce Biotechnology). This kit contains Immobilized Cobalt Chelate, ProFound Lysis Buffer, BupH TM Tris Buffered Saline (TBS), and Handee TM Mini-Spin Columns. After overnight culture of bacterial clones containing the His-tagged ARH constructs and GST-LDLR fusion plasmids, 3 mL medium was inoculated into 100 mL LB medium supplemented with kanamycin (50 g/mL) or ampicillin (100 g/mL) and cultured at 37 for 4 hours with shaking. Protein expression was induced by the addition of IPTG (1 mM for His-ARH and 0.1 mM for GST-LDLR constructs). The bacteria were incubated for 2 hours at room temperature, harvested by centrifugation, and resuspended in 1 mL TBS (25 mM Tris HCl, 0.15 M NaCl, pH 7.2) per 5 mL of the original culture medium. The bacteria were then lysed using lysis buffer, debris were removed by centrifugation, and the supernatant of bacteria transfected with His-tagged ARH was washed 5 times with TBS containing 40 mM imidazole and incubated with immobilized cobalt chelate in spin columns on a rotating platform at 4 overnight. The immobilized his-tagged fusion proteins were washed 5 times with TBS containing 40 mM imidazole, and then washed supernatants of lysed IPTG-stimulated E. coli transfected with GST-fusion LDLR were applied. The immobilized cobalt chelate was incubated at 4 for 1 hour with gentle rocking on a rotating platform, washed 5 times with TBS containing 40 mM imidazole, and the elution buffer containing 290 mM imidazole was added. The supernatants were resuspended in 50 L of sample loading buffer (0.5M Tris-HCl, 10% glycerol, 2% SDS, 5% -mercaptoethanol, and 1% bromophenol blue), and heated at 100 for 5 min. Aliquots (15 L) of the cell lysates and eluates of the immobilized cobalts chelates were size-fractionated on duplicate 12% polyacrylamide gels, transferred to PVDF membranes (Millipore, Watertown, MA), blocked with 5% dry milk in PBS, and blotted using mouse monoclonal antibodies for His6 (1:10,000 dilution) and LDLR (1:100). The mouse monoclonal antibody for His6 was purchased from Amersham Biosciences (Piscataway, NJ), and a goat polyclonal antibody directed against the C-terminal residues of the human LDLR (C-20) was obtained from Santa Cruz Biotechnology, Inc.
Results
Clinical Characteristics of the Subjects
The clinical characteristics of the 391 subjects with hypercholesterolemia and the 495 control subjects are summarized in Table 2 . The groups differed with regard to age and sex, while BMI, SBP, DBP, TC, TG, FPG, HbA1c were all significantly higher in the hypercholesterolemia group than the control group. These results reflected the metabolic disorders associated with hypercholesterolemia; however, no significant difference was noted between the two groups with respect to HDL-C.
Detection of Genetic Variants
In screening for polymorhisms using 48 unrelated subjects, we found 9 novel polymorphisms of the ARH gene: the 5'-flanking region contained a T ( 1303) to C polymorphism ( 1303T C), and there were nucleotide substitutions 1303 bp upstream from ATG [G ( 1233) to C ( 1233G C), G ( 1060) to A ( 1060G>A), A ( 928) to C ( 928A C), G ( 177) to A ( 177G A), and G ( 90) to C ( 90G C)]. In addition, there was C167 to T in exon 2, a nucleotide substitution 167 bp downstream from ATG resulting in replacement of threonine by methionine at codon 56 (Thr56Met); G161 to A (161G A) in intron 3, a nucleotide substitution 161 bp downstream from exon 3; and T2304 to C (2304T C) in exon 9, a nucleotide substitution 2304 bp downstream from ATG. Furthermore, we confirmed the existence of 9 other polymorphisms that had been reported previously, including insertion of 138AG (insAG) in to nintron 5 at 138 bp downstream from exon 5; G604 to T in exon 6, a nucleotide substitution 604 bp downstream from ATG that resulted in the replacement of proline by serine at codon 202 (Pro202Ser); G654 to A (654G A) in exon 7, a nucleotide substitution 654 bp downstream from ATG; and G2299 to T (2299G T) in exon 9, a nucleotide substitution 2299 bp downstream from ATG. In the 3'-flanking region, there was 1923C to T (1923C T), a nucleotide substitution 1923 bp downstream from TGA, as well as 2043G to A (2043G A), 2116T to C (2116T C), 2582T to C (2582T C), and 2727G to T (2727G T). All genotype frequencies were consistent with the Hardy-Weinberg equilibrium (p 0.05). These polymorphisms and allele frequencies are summarized in Table 3 , and the ARH gene structure is shown in Fig. 1A , B. SNPs with a frequency of 0.03 were excluded from further analysis 22) .
Haplotype Estimation
We performed linkage disequibrium analysis to determine whether a particular linkage was present between any of these polymorphisms. As a result, 8 polymorphisms (insAG, Pro202Ser, 654G A, 2299G
T, 1923C T, 2043G A, 2116T C, and 2582T C) were found to be completely linked (|D'| 1, r 2 1), and 2 other polymorphisms ( 928A C and This polymorphism has been identified (12), but not registered in GenBank. Abbreviations: ins, insertion; Pro, proline; Ser, serine; Thr, threonine; Met, methionine. 161G A) were perfectly linked (|D'| 1, r 2 1). Next, we performed haplotype estimation using 5 polymorphisms with a frequency of ≥ 0.03 22) that were not completely linked. As a result, 2 haplotype blocks were detected, with one block consisting of 1303T C polymorphism and the other consisting of 161G A, 654G A, and 2727G T polymorphism. In the latter haplotype block, 4 different haplotypes were identified: GGT (43.8%), GAG (42.7%), GGG (8.3%), and AGT (5.2%). These data are summarized in Fig. 1C .
Association Between ARH and Hypercholesterolemia
We selected 5 ARH polymorphisms that were not incomplete linkage disequibrium ( 1303T C, 1233G C, 161G A, 654G A, and 2727G T) for the association study. Weinberg equilibrium in both groups. In our population, there was no significant difference of any genotype/allele frequencies in relation to the incidence of hypercholesterolemia (Table 4) . Furthermore, there was no significant association between any of the haplotypes and hypercholesterolemia by the Z-test, and age-and gender-adjusted analysis also showed no significant associations ( Table 5) .
Clinical Phenotype of the Thr56Met Mutation in Exon 2 of ARH
We detected one individual heterozygous for missense Thr56Met mutation in the PTB domain when we screened 48 unrelated subjects. Because this missense mutation was located on the very important functional domain, we screened 1,800 Japanese participants in the Suita study. We detected only 4 individuals who were heterozygous for Thr56Met, and all 4 people had hypercholesterolemia and were treated with medications (their lipid profiles before treatment were unknown to maintain anonymity). To confirm that Thr56Met was linked to hypercholesterolemia, we screened another sample of 384 unrelated Japanese with diabetes mellitus, and detected 4 patients who were heterozygous for Thr56Met. The clinical characteristics of these 4 patients are summarized in Table 6 . They all had hypercholesterolemia, and their average TC and LDL-C levels were 276 13.8 and 185 7.37 mg/dL, respectively. They also all had hypertension and diabetes mellitus.
Functional Analysis of the Thr56Met Mutation
The Thr56Met mutation was located in the functional domain that binds to LDLR; therefore, we Abbreviations: NC, normal controls; HC, hypercholesterolemic subjects; OR, odds ratio; CI, confidence interval; A and a, alleles of polymorphism with higher and lower frequencies, respectively.
Comparison of genotype distribution adjusted for gender and age (multiple logistic analysis).
Comparison of allele distribution adjusted for gender and age (multiple logistic regression analysis). compared the sequence alignment of human ARH protein around Thr56Met with the sequences of mouse, frog (X. laevis), and zebrafish ARH proteins, and found that Thr56Met was a very highly conserved residue (Fig. 2) . We then performed pull-down experiments to compare the binding of wild-type and mutant ARH proteins to the LDLR; however, we found no significant differences in binding affinity to LDLR between wild-type and mutant ARH (data not shown).
Discussion
In the present study, we used the candidate gene approach to explore whether the gene encoding ARH, which is a protein with an important role in the internalizing or trafficking of LDLR, had a role in the pathogenesis of hypercholesterolemia. We screened for polymorphisms of the ARH gene and identified 18 different polymorphisms, including new 9 polymorphisms which we identified, of which 6 were located in a 2-kb zone of the 5'-flanking region, 2 were in Amino acids that are identical in all four species are boxed. Thr56Met is a highly conserved residue located in the functional domain.
ARH Protein Structure
the introns, 5 were in the exons, and 5 were in the 3'-flanking region. These polymorphisms included 2 SNPs that caused missense variations. We also found 2 haplotype blocks in the ARH gene. There were no significant associations between any of the ARH polymorphisms or haplotypes and common hypercholesterolemia in our Japanese subjects. Even the 2 missense variations of the gene were not significantly associated with hypercholesterolemia. Previously, a number of common missense variants of ARH have been identified 12, 15, 16) , but none appear to influence the plasma cholesterol level in the general population 15, 23) . We also identified a rare (0.22%) Thr56Met missense mutation in exon 2 of the ARH gene, and found that all of the subjects heterozygous for this mutation had hypercholesterolemia. The PTB domains of adaptor proteins bind a canonical sequence motif (NPVY sequence) in the cytoplasmic tail of the LDLR that is required for LDLR-mediated endocytosis 8, 9) . He et al. demonstrated that the PTB domain of ARH binds the cytoplasmic tail of the LDLR in vitro and that an intact NPVY sequence is required for this binding 10) . Davis et al. reported that familial hypercholesterolemia can result from a missense mutation (Y807C) in the cytoplasmic domain of the LDLR, the so-called JD mutation 24) , a mutation which markedly reduces the interaction between ARH and the tail of the LDLR 10) . Because the Thr56Met missense mutation is located in the functional domain of the ARH, which binds to the tail of the LDLR, it is possible that this mutation might reduce the removal of LDL from the plasma. Although ARH has only been reported to be associated with autosomal recessive hypercholesterolomia, we demonstrated hypercholesterolemia arising from a heterozygous mutation of this gene. All the reported mutations of ARH are predicted to introduce premature stop codons, either as a result of a point mutation or a frameshift. With these mutations, neither ARH mRNA nor ARH protein is detected, probably due to nonsense-mediated decay 7, 12, 14, 16, 25) . Thr56Met is a missense mutation, so it can be predicted that the production of normal levels of wildtype and mutant ARH protein would lead to competitive inhibition of binding to the LDLR. Furthermore, the incidence of heterozygosity for Thr56Met was 1 in 450 (4 out of 1,800 unrelated subjects) in our study, which is similar to that for heterozygous FH (1 in 500). These findings suggested that Thr56Met mutation might also cause hypercholesterolemia in its autosomal dominant form. Although we could not detect dysfunction of the ARH mutant by a pull-down experiment that examined binding to the LDLR, we concluded that this mutation was responsible for familial hypercholesterolemia because the substitution affected a highly conserved and functional domain. It is possible that the mutation alters the interaction with or turnover of another protein involved in cholesterol metabolism.
In conclusion, we identified a novel heterozygous C to T transversion (c.167C G) in exon 2 of the ARH gene that should result in a p.Thr56Met substitution in the evolutionarily highly conserved PTB region of ARH protein, a domain that has an important role in binding to LDL receptor. We also found that all patients with this novel mutation had hypercholesterolemia resembling FH. Further investigations, including functional analysis or familial linkage analysis, of the ARH gene are still needed.
